Bharat biotech limited, Biotechnology company

Officials of the World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said on Monday.Speaking to ANI, Dr Singh also informed that India has been offered 7.5 million doses of Moderna vaccine through WHO's COVID-19 Vaccines Global Access (COVAX) program.The WHO Regional Director said, "Pfizer, AstraZeneca, Moderna, Johnson and Johnson, Sinovac and Sinopharm have been granted EUL by the WHO. For COVXIN, an expression of interest for EUL has been made to WHO by Bharat Biotech. WHO has already conducted a pre-submission meeting with the company following which a dossier has been submitted by Bharat Biotech to WHO in early July. The dossier is currently under review by the technical experts for consideration of EUL."Cautioning about the possibility of the Delta variant of coronavirus becoming the most dominant COVID strain, Dr Singh said, "Delta variant has spread to over 100 countries, the way its spreading is likely to soon become the most dominant COVID strain globally.""Among all variants of concern, Delta spreads most rapidly. The rapid spread means more cases, leading to more pressure on health systems and more deaths," she said.The WHO South-East Asia director noted that globally, COVID cases and fatalities were again on the rise."The more we allow the virus to spread, the more it will evolve, resulting in more variants. We need to ensure that public health and social measures are implemented continuously. The interventions proven to be effective even against the delta variant," she said.Dr Singh also urged people to act 'urgently' to contain the spread of the COVID-19 virus and aggressively scale up vaccination especially of the vulnerable population for containment of the possible third wave."People are longing to go back to their normal lives which is understandable. However, we have to be reminded of the huge risk of letting our guards down. We witnessed that very recently and continue to do so globally even today. If we take the precautions, get vaccinated and leave no room for the virus to infect us, all of us together can contain the spread of the virus," she noted.She further informed that for the past ten consecutive weeks, COVID cases have been continuously increasing in some Eastern Mediterranean, European and Southeast Asian countries.Dr Singh also noted that cases are on a decline in India, Nepal, and Maldives. "However, the situation continues to be a concern,' she said."The pandemic isn't over anywhere. We must continue to strengthen our capacity. There is absolutely no room for complacency. We need to prevent another surge and scale up our response capacity along with our vaccination programmes," she added.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Bharat Biotech LimitedFOLLOW

Bharat biotech limited, Latest News

Hyderabad, July 30 Vice President, M. Venkaiah Naidu on Friday urged the scientific fraternity to focus on expediting ... ...

Vice President M Venkaiah Naidu on Friday visited pharma major Bharat Biotech's COVID-19 vaccine manufacturing facility in Hyderabad. ...

After trials on adults, COVID-19 vaccine manufacturing companies Biological E and Novavax are being encouraged to conduct a study on paediatrics, said Member-Health of NITI Aayog Dr VK Paul on Tuesday. ...

Trials for Bharat Biotech's Covid-19 vaccine Covaxin on children are underway and results are expected to be released by September, All India Institute of Medical Sciences (AIIMS) director Randeep Guleria informed. ...

Bharat Biotech on Friday said it has terminated agreements it had signed with two Brazilian companies - Precisa Medicamentos and Envixia Pharmaceuticals LLC to introduce its Covid-19 Covaxin in Brazil. ...

As part of its COVID-19 vaccination trials for children, Bharat Biotech is likely to administer the second dose of Covaxin to children aged between 2 and 6 years next week, sources said on Thursday. ...

Emergency approval for Zydus Cadila's Covid-19 vaccine may take a few more days with the Ahmedabad-based pharma company set to submit additional data related to immunogenicity and safety of its Zycov-D vaccine to the Drugs Controller General of India ...

Officials of the World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poon ...